Always great insight Doc! I understand the company may be aiming for a headline like 'Best Blarcamesine cohort can halt AD progression', but I agree these findings are hypothesis-generating and could inadvertently impact the approval chances.
What’s your perspective on the seemingly promising OLE results hinted at by Dr. Sabbagh’s AD/PD 2025 oral presentation title: 'Phase IIB/III Attention-AD trial Over three years of continuous treatment with oral Blarcamesine continues to SIGNIFICANTLY BENEFIT early Alzheimer’s Disease patients'; While it doesn’t address dropout rates or safety, does it suggest that efficacy—at least based on ADAS-Cog13—is sustained over three years? This was one of my main concerns, especially given the delayed separation in efficacy until 48 weeks during the earlier trial phase.
Market Data 
Markets 
AI
